Materials 2011, 4, 801-815; doi:10.3390/ma4040801

Article

Structural Consideration in Designing Organotin Polyethers to Arrest the Growth of Breast Cancer Cells In Vitro

Charles E. Carraher Jr. 1,2, Michael R. Roner 3,*, Kimberly Shahi 4 and Girish Barot 5

1 Department of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, FL 33431, USA; E-Mail: carraher@fau.edu (C.E.C.)
2 Florida Center for Environmental Studies, Palm Beach Gardens, FL 33410, USA
3 Department of Biology, University of Texas Arlington, Arlington, TX 76019, USA
4 Department of Biological Sciences, University of North Texas, Denton, TX 76203, USA; E-Mail: kimberly.shahi@unt.edu (K.S.)
5 Department of Biology, Boston University, Boston, MA 02215, USA; E-Mail: girishbarod@yahoo.com (G.B.)

* Author to whom correspondence should be addressed: E-Mail: roner@uta.edu; Tel.: +1-817-272-1302.

Received: 11 February 2011; in revised form: 4 April 2011 / Accepted: 8 April 2011 / Published: 15 April 2011

Abstract: The ability to inhibit cancer is inherent in organotin materials yet the structural relationships that regulate/direct this activity remains unknown. We measured antitumor activity using a matched pair of cell lines MDA-MB-231 cells that are estrogen-independent, estrogen receptor negative and MCF-7 cells, a cell line that is estrogen receptor (ER) positive. Those polyethers that contained a O-phenyl unit were able to significantly inhibit the non-estrogen sensitive cell line but were much less effective against the estrogen sensitive cell line; that is, the human breast cancer cell line MDA-MB-231 showed better test results for polymers derived from diols containing the O-phenyl moiety than the breast cancer cell line MCF-7, a well-characterized estrogen receptor positive control cell line. Those polyethers that did not contain the O-phenyl unit inhibited both cell lines approximately the same. The differential activity of the O-phenyl-containing polyethers is likely due to the estrogen-sensitive cells combining with some of the organotin polyethers minimizing their ability to inhibit cell growth.
1. Introduction

The ability to inhibit cancer by organotin materials has been known for about 80 years [1]. Even so, identification of structural relationships has not been accomplished [2-7]. We have been involved in the synthesis and structural and biological characterization of metal-containing polymers. Recently, much of the biological effort has focused on organotin, platinum and Group IVB metalloocene-containing polymers [3,5,8-26]. The topics of organotin polymers [3,5], platinum polymers [22] and Group IVB metalloocene-containing polymers [24] have been recently reviewed. The interaction of monomeric or small molecule organotin compounds and breast cancer has been previously described [27-32].

We have noticed in our general testing of the ability of various organotin polyethers to inhibit different cancer cell lines that in certain cases the human breast cancer cell line MDA-MB-231, that is estrogen-independent, estrogen receptor negative, showed better test results than the breast cancer cell line MCF-7, a well-characterized estrogen receptor positive control cell line (cells are positive for cytoplasmic estrogen receptors) and therefore are a useful in vitro model of breast cancer to study the role of estrogen in breast cancer. Here, we describe some of these results.

2. Results and Discussion

2.1. Measurement Types

Two types of measurements are generally employed to report the ability of materials to inhibit cell growth. The first is the growth inhibition, GI, value. Generally the concentration at which 50% growth inhibition occurs, GI50, is reported. The second value is the chemotherapeutic index (CI) value. The CI is employed to compare the toxicity of a drug on normal cell lines (or other “base-line” cell line) to its toxicity to a cancer (or second) cell line. The CI50 is the GI50 drug concentration for the normal (or base line) cell line divided by the GI50 drug concentration for the cancer cell line. Values in excess of two are generally considered significant.

To gain a better picture of the relationship between polymer and possible preference for one cell line over the other one additional column have been added to each table. For the GI50 values, a column noting the ratio of the GI50 for the MDA cell line divided by the GI50 for the MCF-7 cell line, MDA/MCF-7, has been added. Here, values greater than one are consistent with lower concentrations of drug inhibiting the growth of the MCF-7 cells compared to the MDA cells. Values less than one are consistent with inhibition of the MDA cells occurring at lower concentrations than for the MCF-7 cells. When describing the CI some researchers employ the similar terms ED or effective dose in place of the GI value for the cancer cells and LD or lethal dose in place of GI for the healthy cell line, here the WI-38 cell line (strain line ATCC CCL-75). Thus, CI50 = LD50/ED50. For the CI50 values the added
column contains the CI\textsubscript{50} for the MDA cell line divided by the CI\textsubscript{50} for the MCF-7 cell line, CI-MDA/CI-MCF-7. Here, values greater than one are consistent with inhibition of the MDA cells occurring at lower concentrations than for the MCF-7 cells. And, values less than one are consistent with lower concentrations of drug inhibiting the growth of the MCF-7 cells compared to the MDA cells. The values contained in the added columns should be related since the CI values are “normalized” with the same WI-38 cell line values.

2.2. Aliphatic-Derived Organotin Polyethers

Tables 1 and 2 contain data from organotin polyethers derived from aliphatic diols (Figure 1).

**Table 1.** GI\textsubscript{50} concentrations (micrograms/mL) for organotin polyethers from ethylene glycols and methylene diols for MDA and MCF-7 cell lines.

| Sample                  | Cell Line   |
|-------------------------|-------------|
|                         | WI-38 | MDA | MCF-7 | MDA/MCF-7 |
| Bu\textsubscript{2}Sn/Ethylene glycol | 0.90(0.10) | 0.30(0.23) | 0.60(0.05) | 0.50 |
| Bu\textsubscript{2}Sn/Diethylene glycol | 1.20(0.10) | 1.20(0.10) | 1.20(0.10) | 1.0  |
| Bu\textsubscript{2}Sn/Triethylene glycol | 1.10(0.10) | 1.20(0.10) | 1.20(0.11) | 1.0  |
| Bu\textsubscript{2}Sn/Pentaethylene glycol | 0.05(0.01) | 0.90(0.01) | 1.20(0.01) | 0.75 |
| Bu\textsubscript{2}Sn/PEG(400),DMSO | 3.50(0.29) | 1.90(0.16) | 2.80(0.22) | 0.68 |
| Bu\textsubscript{2}Sn/PEG(400),H\textsubscript{2}O | 0.28(0.03) | 2.40(0.22) | 1.40(0.10) | 1.7  |
| Bu\textsubscript{2}Sn/PEG(8000),DMSO | 0.11(0.01) | 3.20(0.29) | 3.20(0.30) | 1.0  |
| Bu\textsubscript{2}Sn/PEG(8000),H\textsubscript{2}O | 1.00(0.10) | 10.00(0.93) | 10.00(0.96) | 1.0  |
| Bu\textsubscript{2}Sn/PEG(10000),DMSO | 4.20(0.33) | 10.00(0.89) | 5.80(0.47) | 1.7  |
| Bu\textsubscript{2}Sn/PEG(10000),H\textsubscript{2}O | 1.00(0.10) | 10.00(0.97) | 10.00(1.00) | 1.0  |

Values given in ( ) are standard deviations for each set of measurements.

**Table 2.** Chemotherapeutic Index-50% for the organotin polyethers from ethylene glycols and methylene diols for MDA and MCF-7 cell lines.

| Sample                  | Cell Line   |
|-------------------------|-------------|
|                         | WI-38/ | WI-38/ | WI-38/ | CI-MDA/ |
|                         | WI-38 | MDA | MCF-7 | CI-MCF-7 |
| Bu\textsubscript{2}Sn/Ethylene glycol | 1.0 | 3.0 | 1.5 | 2.0  |
| Bu\textsubscript{2}Sn/Diethylene glycol | 1.0 | 1.0 | 1.0 | 1.0  |
| Bu\textsubscript{2}Sn/Triethylene glycol | 1.0 | 0.92 | 0.92 | 1.0  |
| Bu\textsubscript{2}Sn/Pentaethylene glycol | 1.0 | 0.06 | 0.04 | 1.5  |
Table 2. Cont.

| Sample                        | Cell Line | WI-38/ | WI-38/ | WI-38/ | CI-MDA/ |
|-------------------------------|-----------|--------|--------|--------|---------|
|                               | WI-38     | MDA    | MCF-7  | CI-MCF-7 |
| Bu₂Sn/PEG(400), DMSO         | 1.0       | 1.8    | 1.3    | 1.4     |
| Bu₂Sn/PEG(400), H₂O          | 1.0       | 0.12   | 0.20   | 0.60    |
| Bu₂Sn/PEG(8000), DMSO        | 1.0       | 0.03   | 0.03   | 1.0     |
| Bu₂Sn/PEG(8000), H₂O         | 1.0       | 0.10   | 0.10   | 1.0     |
| Bu₂Sn/PEG(10000), DMSO       | 1.0       | 0.42   | 0.72   | 0.58    |
| Bu₂Sn/PEG(10000), H₂O        | 1.0       | 0.10   | 0.10   | 1.0     |
| Bu₂Sn/Ethylene glycol        | 1.0       | 21     | 5.2    | 4.0     |
| Bu₂Sn/1,3-Propanediol        | 1.0       | 0.43   | 0.17   | 2.5     |
| Bu₂Sn/1,4-Butanediol         | 1.0       | 1.6    | 1.1    | 1.5     |
| Bu₂Sn/1,5-Pentanediol        | 1.0       | 4.0    | 0.86   | 4.7     |
| Bu₂Sn/1,6-Hexanediol         | 1.0       | 1.0    | 0.79   | 1.3     |
| Bu₂Sn/1,7-Heptanediol        | 1.0       | 3.6    | 0.86   | 4.2     |
| Bu₂Sn/1,8-Octanediol         | 1.0       | 1.6    | 0.31   | 5.2     |

**Figure 1.** Repeat unit for the polymers derived from the reaction of organotin dihalides with various ethylene glycols (left) and with methylene oxide diols (right) where R is butyl and R¹ represents simple chain extension.

Characterization of these materials has been described [11,33]. The values of GI₅₀ MDA/ GI₅₀ MCF-7 as well as the corresponding CI₅₀ MDA/ CI₅₀ MCF-7 values are around one consistent with the organotin polyethers not having a marked preference for either cell line. The aliphatic diols themselves do not exhibit cancer cell inhibition. The values of GI₅₀ MDA/ GI₅₀ MCF-7 are about one (average = 0.95) and are consistent with the organotin polyethers not having a preference for either cell line. The corresponding CI₅₀ MDA/ CI₅₀ MCF-7 values are around two (average = 2.0) consistent with the organotin polyethers having some preference for inhibiting the non-estrogen MDA cell line at lower concentration of drug than the estrogen-sensitive MCF-7 cells.

2.3. Hydroquinone and Hydroquinone-Derived Organotin Polyethers

Characterization of these products has been described [34]. Tables 3 and 4 contain similar GI₅₀ and CI₅₀ data for organotin polyethers derived from hydroquinone and hydroquinone derivatives (Figure 2).

The GI₅₀ MDA/ GI₅₀ MCF-7 values are much less than one (average = 0.068) while the CI₅₀ MDA/ CI₅₀ MCF-7 values are much greater than one (average = 20). These are markedly different than for the organotin polyethers derived from aliphatic diols. Here, inhibition occurs at a much lower...
concentration for the MDA cell line in comparison to the MCF-7 cell line. The diols in this study showed little or no inhibition of the cancer cell lines.

**Table 3.** GI₅₀ concentrations (micrograms/mL) for dibutyltin polyethers from hydroquinone and hydroquinone derivatives for MDA and MCF-7 cell lines.

| Sample                          | Cell Line     | WI-38 | MDA   | MCF-7 | MDA/MCF-7 |
|--------------------------------|---------------|-------|-------|-------|-----------|
| Methoxyhydroquinone            |               | 2.0(0.3) | 0.09(0.01) | 1.7(0.4) | 0.053     |
| Tert-Butylhydroquinone         |               | 1.8(0.5) | 0.23(0.01) | 2.4(0.5) | 0.096     |
| 2,5-Di-tert-Butylhydroquinone  |               | 2.2(0.5) | 0.22(0.01) | 1.8(0.5) | 0.12      |
| Methylhydroquinone             |               | 2.6(0.5) | 0.036(0.1) | 1.7(0.4) | 0.021     |
| Phenylhydroquinone             |               | 0.21(.03) | 0.11(0.01) | 1.7(0.4) | 0.065     |
| Hydroquinone                   |               | 2.0(0.5) | 0.045(0.01) | 1.7(0.5) | 0.026     |
| 2,3-Dicyanohydroquinone        |               | 2.4(0.5) | 0.22(0.09) | 1.9(0.5) | 0.12      |
| Bromophydroquinone             |               | 0.25(0.1) | 0.085(0.01) | 2.7(0.4) | 0.031     |
| Chlorohydroquinone             |               | 1.8(0.3) | 0.086(0.01) | 1.7(0.4) | 0.051     |
| 2,5-Dichlorohydroquinone       |               | 1.9(0.3) | 0.38(0.09) | 2.6(0.5) | 0.15      |
| Tetrachlorohydroquinone        |               | 2.2(0.5) | 0.12(0.01) | 3.9(0.5) | 0.031     |
| 2,5-Dihydroxybenzaldehyde      |               | 2.0(0.5) | 0.13(0.01) | 2.4(0.5) | 0.054     |

Values given in ( ) are standard deviations for each set of measurements.

**Table 4.** Chemotherapeutic Index-50% for the polymers formed from reaction of dibutyltin dichloride and hydroquinone and hydroquinone derivatives for MDA and MCF-7 cell lines.

| Sample                      | Cell Line     | WI-38/ MDA | WI-38/ MCF-7 | CI-MDA/ CI-MCF-7 |
|-----------------------------|---------------|------------|--------------|------------------|
| Methoxyhydroquinone         |               | 1.0        | 21           | 1.2              | 1.8              |
| Tert-Butylhydroquinone      |               | 1.0        | 7.6          | 0.72             | 11               |
| 2,5-Di-tert-Butylhydroquinone|             | 1.0        | 9.8          | 1.2              | 8.2              |
| Methylhydroquinone          |               | 1.0        | 71           | 1.5              | 47               |
| Phenylhydroquinone          |               | 1.0        | 1.9          | 0.12             | 16               |
| Hydroquinone                |               | 1.0        | 43           | 1.1              | 39               |
| 2,3-Dicyanohydroquinone     |               | 1.0        | 11           | 1.2              | 9.2              |
| Bromophydroquinone          |               | 1.0        | 2.9          | 0.090            | 32               |
| Chlorohydroquinone          |               | 1.0        | 21           | 1.1              | 19               |
| 2,5-Dichlorohydroquinone    |               | 1.0        | 4.9          | 0.72             | 6.8              |
| Tetrachlorohydroquinone     |               | 1.0        | 19           | 0.57             | 33               |
| 2,5-Dihydroxybenzaldehyde   |               | 1.0        | 15           | 0.84             | 18               |
Figure 2. Representative structures for some of the hydroquinone and hydroquinone-derived polyethers. The diols are from left to right, top: hydroquinone itself, chlorohydroquinone, phenylhydroquinone, and left to right, bottom: bromohydroquinone, methylhydroquinone, and 2,5-dichlorohydroquinone where $R$ is butyl and $R^1$ represents simple chain extension.

2.4. Hormone-Derived Organotin Polyethers

In our study of a variety of organotin polyethers we included the study of two related hormone-containing products. Characterization of these products has been reported [10, 35, 36].

The first is diethylstilbestrol (DES). Diethylstilbestrol ($4,4'[(1E)-1,2-ethenediyl]bisphenol$), is a synthetic estrogen that mimics estrogen, one of the primary ovarian hormones. It is known by a number of common names including stilbesterol and stilboestrol and sold under a number of names including Apstil, cyren A, distilbene, and stilbetin.

DES was first used in 1938 for women in an effort to prevent miscarriage or premature deliveries. In 1953, a double-blind study showed that DES did little to improve premature deliveries or miscarriage. Even so, it was still widely marketed until the early 1970s for this use. By 1971 it was estimated that 5 to 10 million people were exposed to DES. In 1971 the Food and Drug Administration issued a Drug Bulletin advising physicians to halt prescribing DES. DES was linked to a rare vaginal cancer in female offspring. Further research has shown that DES is a teratogen that can cause malformation of an embryo or fetus.

DES is currently used with animals. Its primary use is to treat urinary incontinence in spayed female cats and dogs. It has also been used to prevent unwanted pregnancy in dogs and cats. DES has been used to treat breast and prostate cancer but its use is limited because of relatively poor water solubility and a wide range of dose-related toxicities that includes nausea and vomiting, venous and arterial thrombosis, and fluid retention. The use of estrogens as potent antiandrogens in hormonal therapy of metastatic prostate cancer has also been described. Thus, there exist several studies that indicate the potential usefulness of DES as a positive drug in the treatment of specific cancers.

The second hormone was dienestrol. Dienestrol, ($4-[4-(hydroxyphenyl)hexa-2,4-dien-3-yl]phenol$), is one of the most widely used sex hormones. It was initially synthesized by Dodd and others in 1938 and
initially patented by both Boots and Hoffman-La Roche in 1949. In the popular literature it is often confused with DES, diethylstilbestrol, but it is a distinct hormone with its own chemical and biological properties. It is sold under a variety of trade names including Farmacyrol, Lipamone, and Retalon-Oral.

Dienestrol is widely used in hormone therapy, mainly hormone replace therapy or more precisely, estrogen replacement therapy.

Tables 5 and 6 contain data for organotin polyethers derived from the hormones diethylstilbestrol, DES, and dienestrol (Figure 3).

**Table 5.** GI<sub>50</sub> concentrations (micrograms/mL) for organotin polyethers derived from diethylstilbestrol (DES) and dienestrol for MDA and MCF-7 cell lines.

| Sample           | Cell Line | WI-38 | MDA  | MCF-7 | MDA/MCF-7 |
|------------------|-----------|-------|------|-------|------------|
| DES              | WI-38     | 0.25(0.2) | 0.05(0.01) | 0.64(0.05) | 0.078       |
| Me<sub>2</sub>Sn/DES | MDA   | 1.60(0.5) | 0.47(0.04) | 0.66(0.05) | 0.71       |
| Et<sub>2</sub>Sn/DES   | MCF-7    | 0.05(0.01) | 0.16(0.01) | 0.55(0.05) | 0.29       |
| Pr<sub>2</sub>Sn/DES   | MDA/MCF-7 | 2.30(0.5) | 0.09(0.01) | 0.66(0.05) | 0.14       |
| Bu<sub>2</sub>Sn/DES   | WI-38     | 2.50(0.5) | 0.05(0.01) | 0.62(0.05) | 0.081      |
| Cy<sub>2</sub>Sn/DES   | MDA      | 0.22(0.02) | 0.21((0.02) | 0.50(0.05) | 0.42       |
| Ph<sub>2</sub>Sn/DES   | MCF-7     | 2.30(0.5) | 0.11(0.02) | 0.65(0.05) | 0.17       |
| Dienestrol        | MDA/MCF-7 | 0.25(0.2) | 0.11(0.02) | 0.44(0.05) | 0.25       |
| Me<sub>2</sub>Sn/Dienestrol | WI-38 | 1.5(5) | 0.13(0.06) | 0.76(0.06) | 0.17       |
| Et<sub>2</sub>Sn/Dienestrol | MDA | 1.4(5) | 0.04(0.01) | 0.81(0.06) | 0.049      |
| Pr<sub>2</sub>Sn/Dienestrol | MCF-7 | 0.31(2) | 0.21(0.02) | 0.69(0.05) | 0.30       |
| Bu<sub>2</sub>Sn/Dienestrol | WI-38 | 0.06(0.01) | 0.03(0.01) | 0.76(0.05) | 0.039      |
| Cy<sub>2</sub>Sn/Dienestrol | MDA | 0.26(2) | 0.24(0.02) | 0.70(0.05) | 0.34       |
| Ph<sub>2</sub>Sn/Dienestrol | MCF-7 | 0.19(2) | 0.31(0.04) | 0.70(0.05) | 0.44       |

Values given in ( ) are standard deviations for each set of measurements.

**Table 6.** Chemotherapeutic Index-50% for the organotin polyethers derived from diethylstilbestrol (DES) and dienestrol for MDA and MCF-7 cell lines.

| Sample           | Cell Line | WI-38/ WI-38 | WI-38/ WI-38 | WI-38/ WI-38 | CI-MDA/CIMCF-7 |
|------------------|-----------|---------------|---------------|---------------|-----------------|
| DES              | WI-38     | 1.0           | 5.0           | 3.9           | 0.39            |
| Me<sub>2</sub>Sn/DES | MDA | 1.0           | 3.4           | 2.5           | 1.4             |
| Et<sub>2</sub>Sn/DES   | MCF-7    | 1.0           | 0.31          | 0.09          | 3.4             |
| Pr<sub>2</sub>Sn/DES   | WI-38     | 1.0           | 2.6           | 3.5           | 0.74            |
| Bu<sub>2</sub>Sn/DES   | MDA      | 1.0           | 50            | 4.0           | 13              |
| Cy<sub>2</sub>Sn/DES   | MCF-7     | 1.0           | 1.0           | 4.4           | 0.23            |
| Ph<sub>2</sub>Sn/DES   | WI-38     | 1.0           | 21            | 3.5           | 0.60            |
Here, the GI\textsubscript{50} MDA/ GI\textsubscript{50} MCF-7 are generally much smaller than one (average = 0.30 for DES and 0.22 for dienestrol) while the CI\textsubscript{50} MDA/ CI\textsubscript{50} MCF-7 values are generally much larger than one (average = 4.0 for DES and 8.5 for dienestrol). The values are consistent with these organotin polyethers preferentially inhibiting the MDA non-estrogen sensitive cancer cell line. Further, the values for DES and dienestrol themselves are consistent with a preferential inhibition of the MDA non-estrogen cancer cell line. DES is effective against estrogen receptor positive (ER+) tumors such as the MCF-7 cell line \cite{37-46}. It is possible that some of the drug is bound to the estrogen receptors in the MCF-7 cells making the drug unavailable to act within the cell.

Thus, the results for the two hormones are similar to those found for the hydroquinone and hydroquinone-derived products described in Tables 3 and 4 but different from those derived from simple aliphatic diols Tables 1 and 2. DES and dienestrol have a structural similarity to the hydroquinone products in that all possess an O-phenylene linkage to the organotin. The organotin polyethers derived from aliphatic diols do not possess this linkage.

2.5. Organotin Monomers

Tables 7 and 8 contain GI\textsubscript{50} and CI\textsubscript{50} results for the organotin monomers. The GI\textsubscript{50} MDA/ GI\textsubscript{50} MCF-7 values are about one (average = 1.07) as are the CI\textsubscript{50} MDA/ CI\textsubscript{50} MCF-7 values (average = 1.06). Thus, the results are similar to those found for the aliphatic-derived diols given in Tables 1 and 2 with no marked preference for either cell line. It appears then that the difference in preference between the two cell lines is due to what is linked to the organotin and not the organotin itself.
Table 7. GI<sub>50</sub> concentrations (micrograms/mL) for organotin monomers for MDA and MCF-7 cell lines.

| Sample        | WI-38 | MDA | MCF-7 | MDA/MCF-7 |
|---------------|-------|-----|-------|------------|
| Me<sub>2</sub>SnCl<sub>2</sub> | 0.22(1) | 0.44(1) | 0.66(0.1) | 0.67       |
| Et<sub>2</sub>SnCl<sub>2</sub> | 0.20(1) | 0.64(1) | 0.77(0.1) | 0.83       |
| Pr<sub>2</sub>SnCl<sub>2</sub> | 0.25(1) | 0.47(1) | 0.45(0.1) | 1.0        |
| Bu<sub>2</sub>SnCl<sub>2</sub> | 0.20(0.05) | 1.40(12) | 0.70(0.06) | 2.0       |
| Ph<sub>2</sub>SnCl<sub>2</sub> | 0.25(1) | 0.76(1) | 0.68(0.1) | 1.1        |
| Cy<sub>2</sub>SnCl<sub>2</sub> | 0.20(1) | 0.45(1) | 0.59(0.1) | 0.76       |
| Oc<sub>2</sub>SnCl<sub>2</sub> | 0.30(1) | 0.65(1) | 0.70(0.1) | 0.93       |
| Bz<sub>2</sub>SnCl<sub>2</sub> | 0.20(1) | 0.75(1) | 0.60(0.10) | 1.3       |

Values given in ( ) are standard deviations for each set of measurements.

Table 8. Chemotherapeutic Index-50% for organotin monomers for MDA and MCF-7 cell lines.

| Sample        | WI-38/ MDA | WI-38/ MCF-7 | CI-MDA/ CI-MCF-7 |
|---------------|------------|--------------|------------------|
| Me<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.50 | 0.33 | 1.5 |
| Et<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.31 | 0.26 | 1.2 |
| Pr<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.63 | 0.56 | 1.1 |
| Bu<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.17 | 0.29 | 0.59 |
| Ph<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.33 | 0.37 | 0.89 |
| Cy<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.44 | 0.34 | 1.3 |
| Oc<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.46 | 0.43 | 1.1 |
| Bz<sub>2</sub>SnCl<sub>2</sub> | 1.0 | 0.27 | 0.33 | 0.82 |

3. Experimental Section

3.1. Synthesis and Physical Characterization

Reactions were carried out using the interfacial polycondensation technique. Briefly, an aqueous solution (30 mL) containing the diol (0.00300 mol) and sodium hydroxide (0.0060 mol) was transferred to a one quart Kimax emulsifying jar fitted on top of a Waring Blender (model 1120; no load speed of about 18,000 rpm; reactions were carried out at about 25 °C). Stirring was begun and a hexane solution (30 mL) containing the diorganotin dichloride (0.00300 mol) was rapidly added (about 3-4 seconds) through a hole in the jar lid using a powder funnel. The resulting solution was blended for 15 seconds. The precipitate was recovered using vacuum filtration and washed several times with deionized water and hexane to remove unreacted materials and unwanted by-products. The solid was washed onto a glass petri dish and allowed to dry at room temperature. Chain length was determined employing light scattering photometry using a Brice-Phoenix BP 3000 Universal Light Scattering Photometer. Refractive indices were obtained using a Bauch & Lomb Model 3-L refractometer.
Additional analysis was carried out including Mössbauer spectroscopy, infrared spectroscopy, NMR spectroscopy, and MALDI MS [4,10,11,13,18,33-36].

3.2. Biological Characterization

The cell lines MDA-MB-231, that is estrogen-independent, estrogen receptor negative, and the breast cancer cell line MCF-7 a cell line isolated in 1970 from a 69-year-old Caucasian woman. MCF-7 is the acronym of Michigan Cancer Foundation. MCF-7 cells are a well-characterized estrogen receptor (ER) positive control cell line (cells are positive for cytoplasmic estrogen receptors) and therefore are a useful in vitro model of breast cancer to study the role of estrogen in breast cancer. Cells are also positive for cytokeratin and negative for desmin, endothelin, GFAP, neurofilament, vimentin. Both cell lines were obtained from NCI and maintained in MEM supplemented with 10% fetal bovine serum at 37 °C in a 5% carbon dioxide atmosphere.

For testing of the compounds, cells were harvested, counted, and plated into 96-well plates at 1 × 10^4 cells per well in MEM supplemented with 10% fetal bovine serum, and incubated for 24 hours at 37 °C in a 5% carbon dioxide atmosphere. A stock solution of the compound was prepared in DMSO at a known concentration. On day two the cell media was removed and replaced with RPMI-1640 supplemented with 10% fetal bovine serum and the indicated drug concentrations. Seventy-two hours later the cells were assayed for proliferation using the CellTiter 96® Aqueous One Solution Cell Proliferation Assay by Promega Corporation. Assays are performed by adding a small amount of the CellTiter 96 Aqueous One Solution Reagent directly to culture wells, incubating for 1–4 hours and then recording absorbance at 490 nm with a 96-well plate reader. The quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture.

All cytotoxicity values are calculated against a base-line value for each line that was generated from “mock-treatment” of the normal and tumor cells lines with media supplemented with all diluents used to prepare the chemotherapeutic compounds. For example, if the compounds were dissolved in DMSO and serial dilutions prepared in MEM to treat the cells, then the mock-treated cells were “treated” with the same serial dilutions of DMSO without added chemotherapeutic compound. This was done to ensure that any cytotoxicity observed was due to the activity of the compound and not the diluents. For the studies reported here, the mock-treatment never resulted in a loss of cell viability of more than one percent, demonstrating that the activity observed was not due to cytotoxicity of any of the diluents used, but was due to activity of the tested compounds.

4. Conclusions

The results are consistent with the organotin polyethers derived from diols containing a O-phenyl moiety exhibiting a much lowered ability to inhibit the MCF-7 estrogen-sensitive cell line in comparison to the MDA non-estrogen cell line. By comparison, those organotin polyethers derived from simple aliphatic diols that do not contain an O-phenyl linkage to the tin exhibit little or no preference towards inhibition of either cell line.

Recently, the ability of ionic tin to exert estrogen-like activity in MCF-7 breast cancer cells was reported [37]. In this paper [37], ionic tin, along with a number of other metal ions, activated the
estrogen receptor-α (ERα). Thus, ionic tin has been shown to interact with MCF-7 cancer cells. Our study employs covalently-bonded tin and it is not known if the current interaction with the two breast cell lines is related to the results of this study, but it is believed that the presence of the organotin moiety alone is not sufficient to itself be responsible for this difference based on the lack of differentiation between the two cell lines found for the organotin monomers themselves. A better conclusion is that the presence of tin allows for all of the organotin polymers to exhibit some inhibition of the cancer cell lines. If the biological activity involves interaction with vacant d-orbitals on the tin, then there may be some similarity since the organotin moiety in the present polyethers also has available d-orbitals. The ER is a known metal-binding protein and this binding probably involves vacant d-orbitals on the metal ions. It is possible that both breast cancer cell lines interact with the available d-orbitals on the tin and that the differentiation is a result of more than simple interaction with the d-orbitals on the tin. Since organotin polyethers containing the Sn-O-phenyl grouping show a lowered ability to inhibit the MCF-7 cell lines then this grouping may facilitate this linking between the organotin polyether and some site associated with the cancer cell line removing the organotin from exerting its inhibitory action at some other site within the MCF-7 cell.

There are several possible consequences related to the difference in ability of different organotin polyethers to inhibit breast cancer cell lines based on the structure of the Lewis base moiety. First, other drugs incorporating known hormones may also demonstrate this preference for inhibiting the growth of non-estrogen sensitive breast cancer cells in comparison to estrogen sensitive breast cancer cells. Second, drugs containing related structures, specifically the O-phenylene or O-aromatic moiety, may also demonstrate a similar behavior. It is not known if this preference is operational when treating living breast cancer patients but it should be watched for, since a number of breast cancer treatments contain drugs that possess O-phenylene or O-aromatic moieties. These drugs include doxorubicin (Figure 4), epirubicin (Figure 5), mitoxantrone (Figure 6) and liposomal doxorubicin (the liposome of doxorubicin shown in Figure 4).

**Figure 4.** Doxorubicin.
Figure 5. Epirubicin.

Figure 6. Mitoxantrone.

Most of the hormones employed in drug replacement therapy, such as DES and dienestrol, also contain this structural moiety. Our bodies contain an abundance of cations such as magnesium, calcium, tin, and iron that chelate with carbonyls and aromatic hydroxyls present in the aforementioned drugs currently employed in the treatment of breast cancer. Each of these cations contain vacant d orbitals that could then form a complex similar to that present in the Sn-O-phenylene moiety that may provide differentiation between the estrogen and non-estrogen sensitive breast cancer cells. Thus, it might be prudent to employ drugs that do not contain the Sn-O-phenylene moiety in treating MCF-7 related breast cancer or at least test for this differentiation.

The results are preliminary and must be viewed as such but do indicate that there exists a difference in the in vitro cell studies reported on here. Much more must be done before more definite conclusions should be reached.
References

1. Collier, W.A. Zur experimentellen therapie der tumoren. I. Die wirksamkeit einiger metallorganischen blei-und zinnverbindungen. Z. Hygiene Infektionkr 1929, 110, 169-174.
2. Saxena, A.K.; Huber, F. Organotin compounds and cancer chemotherapy. Coord. Chem. Rev. 1989, 95, 109-123.
3. Carraher, C. Organotin polymers. In Macromolecules Containing Metal and Metal-Like Elements: Group IVA Polymer; Wiley: Hobokin, NJ, USA, 2005; Volume 4, pp. 263-310.
4. Carraher, C.; Roner, M. Organotin polyethers as potential biomaterials. Materials 2009, 2, 1558-1598.
5. Carraher, C.; Siegmann-Louda, D. Organotin macromolecules as anticancer drugs. In Macromolecules Containing Metal and Metal-Like Elements: Biomedical Applications; Wiley: Hobokin, NJ, USA, 2004; Volume 3, pp. 57-74.
6. Appel, K.E. Organotin compounds: Toxicokinetic aspects. Drug Metabol. Rev. 2004, 36, 763-786.
7. Alama, A.; Tasso, B.; Novelli, F.; Sparatore, F. Organometallic compounds in oncology: Implications of novel organotins as antitumor agents. Drug Discov. Today 2009, 14, 500-508.
8. Carraher, C.; Li, F.; Butler, C. Synthesis and structural characterization of polymers derived from the condensation of organotin dichlorides and the synthetic amino acids p-amonobenzoic acid and ampicillin. J. Polymer Mater. 2000, 17, 377-384.
9. Carraher, C.; Lanz, L. Synthesis and initial structural characterization of organotin polymers containing norfloxacin. J. Polymer Mater. 2003, 20, 91-100.
10. Carraher, C.; Roner, M.R.; Shahi, K.; Ashida, Y.; Barot, G. Synthesis and initial cell line results of organotin polyethers containing diethylstilbestrol. J. Inorg. Organomet. Polymer. Mater. 2008, 18, 180-188.
11. Barot, G.; Shahi, K.R.; Roner, M.R.; Carraher, C.E. Synthesis, structural characterization, and ability to inhibit cancer growth of a series of organotin poly(ethylene glycols). J. Inorg. Organomet. Polymer. Mater. 2007, 17, 595-603.
12. Carraher, C.; Morie, K. Synthesis of organotin polyesters containing ticarcillin. J. Polymer Mater. 2004, 21, 383-391.
13. Barot, G.; Shahi, K.; Roner, M.; Carraher, C. Synthesis, anomalous fiber formation, and preliminary anticancer study of the organotin polyether derived from 2-butylene-1,4-diol. J. Polym. Mater. 2006, 23, 423-436.
14. Carraher, C.; Morie, K. Organotin polyesters from 1,1’-ferrocenedicarboxylic acidO. J. Inorg. Organomet. Polymer. Mater. 2007, 17, 127-133.
15. Carraher, C.; Battin, A.; Shahi, K.; Roner, M. Synthesis, structural characterization, and initial evaluation as anticancer drugs of dibutyltin polyamines derived form various 4,6-diaminopyrimidines. J. Inorg. Organomet. Polymer. Mater. 2007, 17, 631-639.
16. Carraher, C.; Sabir, T.; Roner, M.; Shahi, K.; Bleicher, R.; Roehr, J.; Bassett, K. Synthesis of organotin polyamine ethers containing acyclovir and their preliminary anticancer and antiviral activity. J. Inorg. Organomet. Polymer. Mater. 2006, 16, 249-257.
17. Roner, M.; Carraher, C.; Roehr, J.; Bassett, K. Antiviral and anticancer activity of organotin polymers and reactants derived from norfloxacin and ampicillin. *J. Polymer Mater.* **2006**, *23*, 153-159.

18. Carraher, C.E., Jr.; Roner, M.R.; Barot, G. Organotin-containing Polyethers as Potential Anticancer Drugs. *Canc. Res. J.* **2010**, *3*, 207-232.

19. Roner, M.; Carraher, C.; Dhanji, S.; Barot, G. Antiviral and anticancer activity of cisplatin derives of tilorone. *J. Inorg. Organomet. Polymer. Mater.* **2008**, *18*, 374-383.

20. Roner, M.; Carraher, C.; Dhanji, S.; Barot, G. Antiviral and anticancer activity of cisplatin derivatives of methotrexate. *J. Polymer Mater.* **2007**, *24*, 371-385.

21. Carraher, C.E.; Scott, W.J.; Schroeder, J.A.; Giron, D.J. Poly(Cis-Dihalodiamine Platinum(Ii)) Compounds - Synthesis and Biological-Activity. *J. Macromol. Sci.* **1981**, *A15*, 625-631.

22. Siegmann-Louda, D.; Carraher, C. PolymERIC platinum-containing drugs in the treatment of cancer. In *Macromolecules Containing Metal and Metal-Like Elements. Biomedical Applications*; Wiley: Hobokin, NJ, USA, 2004; Volume 3, pp. 119-192.

23. Carraher, C.; Lopez, I.; Giron, D. *Polymeric platinox derivative of methotrexate for the treatment of virally related juvenile diabetes*; Plenum: New York, NY, USA, 1987; pp 311-324.

24. Carraher, C. Condensation Metallocene Polymers. *JIOMP* **2005**, *15*, 121-145.

25. Carraher, C.E.; Roner, M.R.; Shahi, K.; Ashida, Y.; Barot, G. Synthesis, structural characterization, and anti-cancer evaluation of group IVB-metallocene polyethers containing the synthetic estrogen diethylstilbestrol. *J. Polymer Mater.* **2007**, *24*, 357-369.

26. Roner, M.R.; Carraher, C.E., Jr.; Shahi, K.; Ashida, Y.; Barot, G. Ability of Group IVB metallocene polyethers containing dienestrol to arrest the growth of selected cancer cell lines. *BMC Cancer* **2009**, *9*, 358.

27. Dieras, V.; Beuzeboc, P.; Laurence, V.; Pierga, J.Y.; Pouillart, P. Interaction between Herceptin and taxanes. *Oncology* **2001**, *61 (Suppl. 2)*, 43-49.

28. Kovala-Demertz, D.; Dokorou, V.; Primikiri, A.; Vargas, R.; Silvestru, C.; Russo, U.; Demertzis, M.A. Organotin meclofenamic complexes: Synthesis, crystal structures and antiproliferative activity of the first complexes of meclofenamic acid—novel anti-tuberculosis agents. *J. Inorg. Biochem.* **2009**, *103*, 738-744.

29. Lin, C.W.; Shen, S.C.; Hou, W.C.; Yang, L.Y.; Chen, Y.C. Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. *Mol. Cancer Ther.* **2008**, *7*, 1195-1206.

30. Mang, T.S.; Allison, R.; Hewson, G.; Snider, W.; Moskowitz, R. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. *Cancer J. Sci. Am.* **1998**, *4*, 378-384.

31. Ray, D.; Sarma, K.D.; Antony, A. Differential effects of tri-n-butylstannyl benzoates on induction of apoptosis in K562 and MCF-7 cells. *IUBMB Life* **2000**, *49*, 519-525.

32. Shi, G.; Chen, D.; Zhai, G.; Chen, M.S.; Cui, Q.C.; Zhou, Q.; He, B.; Dou, Q.P.; Jiang, G. The proteasome is a molecular target of environmental toxic organotins. *Environ. Health Perspect.* **2009**, *117*, 379-386.

33. Carraher, C.; Barot, G. Synthesis of organotin polyethers from diols containing varying methylene separators. *Polym. Mater. Sci. Eng.* **2006**, *95*, 535-537.
34. Barot, G.; Roner, M.R.; Naoshima, Y.; Nagao, K.; Shahi, K.; Carraher, C. Synthesis, structural characterization, and preliminary biological characterization of organotin polyethers derived from hydroquinone and substituted hydroquinones. J. Inorg. Organomet. Polymer. Mater. 2009, 19, 12-27.
35. Carraher, C.; Ashida, Y.; Barot, G. Synthesis of organotin polyethers containing the sex hormone dienestrol. Polym. Mater. Sci. Eng. 2009, 101, 1405-1407.
36. Carraher, C.; Ashida, Y.; Barot, G. Organotin polymers from the hormone dienestrol-HR MALDI MS results. Polym. Mater. Sci. Eng. 2007, 97, 462-465.
37. Martin, M.B.; Reiter, R.; Pham, T.; Avellanet, Y.R.; Camara, J.; Lahm, M.; Pentecost, E.; Pratap, K.; Gilmore, B.A.; Divekar, S.; Dagata, R.S.; Bull, J.L.; Stoica, A. Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology 2003, 144, 2425-2436.
38. Fischer, T.; Schomacker, K.; Schicha, H. Diethylstilbestrol (DES) labeled with Auger emitters: potential radiopharmaceutical for therapy of estrogen receptor-positive tumors and their metastases? Int. J. Radiat. Biol. 2008, 84, 1112-1122.
39. Takahashi, N.; Yang, D.J.; Kohanim, S.; Oh, C.S.; Yu, D.F.; Azhdarinia, A.; Kurihara, H.; Zhang, X.; Chang, J.Y.; Kim, E.E. Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 354-362.
40. Heneweer, M.; Muusse, M.; Dingemans, M.; de Jong, P.C.; van den Berg, M.; Sanderson, J.T. Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicol. Sci. 2005, 83, 257-263.
41. Rosendahl, A.; Forsberg, G. Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. Int. J. Oncol. 2004, 25, 1327-1336.
42. Brohee, R.; Nonclercq, D.; Journe, D.N.; Toubeau, G.; Falmagne, P.; Leclercq, G.; Heuson-Stiennon, J.A.; Laurent, G. Demonstration of estrogen receptors and of estrogen responsiveness in the HKT-1097 cell line derived from diethylstilbestrol-induced kidney tumors. In Vitro Cell Dev. Biol. Anim. 2000, 36, 640-649.
43. Zheng, J.; Kulp, S.K.; Zhang, Y.; Sugimoto, Y.; Dayton, M.A.; Govindan, M.V.; Brueggemeyer, R.W.; Lin, Y.C. 17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells. Anticancer Res. 2000, 20, 11-19.
44. Bachmann-Moisson, N.; Barberi-Heyob, M.; Merlin, J.L.; Ledrich, M.L.; Batt, A.M.; Guillemin, F. Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines. Bull. Cancer 1996, 83, 808-815.
45. Reddel, R.R.; Sutherland, R.L. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res. 1987, 47, 5323-5329.
46. Tate, A.C.; Greene, G.L.; DeSombre, E.R.; Jensen, E.V.; Jordan, V.C. Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res. 1984, 44, 1012-1018.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).